General Information:

Id: 1,409
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Larsen CM et al.(2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus N. Engl. J. Med. 356: 1517-1526 [PMID: 17429083]

Interaction Information:

Comment Glycated hemoglobin levels were significantly lower in the anakinra group after 4 weeks than in the placebo group.
Formal Description
Interaction-ID: 9904

drug/chemical compound

Anakinra

decreases_quantity of

complex/PPI

Glycated hemoglobin

Drugbank entries Show/Hide entries for Anakinra
Comment At 13 weeks, beta-cell function increased in the anakinra group and decreased in the placebo group. In particular, the ratio of proinsulin to insulin was markedly lower in the anakinra group.
Formal Description
Interaction-ID: 9969

drug/chemical compound

Anakinra

affects_processing of

gene/protein

INS

in pancreas
Drugbank entries Show/Hide entries for Anakinra or INS
Comment With the dose of anakinra used in this study, no differences in insulin sensitivity were found at 13 weeks.
Formal Description
Interaction-ID: 9975

drug/chemical compound

Anakinra

NOT affects_activity of

Drugbank entries Show/Hide entries for Anakinra
Comment Levels of C-reactive protein were significantly lower after 4 and 13 weeks in the anakinra group than in the placebo group.
Formal Description
Interaction-ID: 10030

drug/chemical compound

Anakinra

decreases_quantity of

gene/protein

CRP

Drugbank entries Show/Hide entries for Anakinra or CRP
Comment Levels of interleukin-6 were significantly lower after 4 and 13 weeks in the anakinra group than in the placebo group.
Formal Description
Interaction-ID: 10031

drug/chemical compound

Anakinra

decreases_quantity of

gene/protein

IL6

Drugbank entries Show/Hide entries for Anakinra or IL6
Comment Treatment with anakinra for 13 weeks did not significantly change the mRNA expression levels of the insulin-regulated genes GLUT4 and PGC-1alpha in biopsy specimens of skeletal muscle.
Formal Description
Interaction-ID: 10032

drug/chemical compound

Anakinra

NOT affects_expression of

gene/protein

SLC2A4

in muscle
Drugbank entries Show/Hide entries for Anakinra
Comment Treatment with anakinra for 13 weeks did not significantly change the mRNA expression levels of the insulin-regulated genes GLUT4 and PGC-1alpha in biopsy specimens of skeletal muscle.
Formal Description
Interaction-ID: 10033

drug/chemical compound

Anakinra

NOT affects_expression of

gene/protein

PPARGC1A

in muscle
Drugbank entries Show/Hide entries for Anakinra
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10035

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

LEP

in blood
Drugbank entries Show/Hide entries for Anakinra
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10038

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

ADIPOQ

in blood
Drugbank entries Show/Hide entries for Anakinra
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10039

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

RETN

in blood
Drugbank entries Show/Hide entries for Anakinra
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10040

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

TNF

in blood
Drugbank entries Show/Hide entries for Anakinra or TNF
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10041

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

CCL2

in blood
Drugbank entries Show/Hide entries for Anakinra or CCL2
Comment Levels of serum adipokines leptin, adiponectin, resistin, tumor necrosis factor alpha, monocyte chemotactic factor 1, and interleukin-8 were not significantly changed at 13 weeks in either the anakinra group or the placebo group.
Formal Description
Interaction-ID: 10042

drug/chemical compound

Anakinra

NOT affects_quantity of

gene/protein

CXCL8

in blood
Drugbank entries Show/Hide entries for Anakinra
Comment The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation.
Formal Description
Interaction-ID: 10043

drug/chemical compound

Anakinra

decreases_activity of

gene/protein

IL1B

Drugbank entries Show/Hide entries for Anakinra or IL1B
Comment The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation.
Formal Description
Interaction-ID: 10044

drug/chemical compound

Anakinra

decreases_activity of

Drugbank entries Show/Hide entries for Anakinra
Comment The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation.
Formal Description
Interaction-ID: 10045

drug/chemical compound

Anakinra

decreases_activity of

phenotype

hyperglycemia

Drugbank entries Show/Hide entries for Anakinra
Comment The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation.
Formal Description
Interaction-ID: 10048

drug/chemical compound

Anakinra

increases_activity of

in pancreas, in pancreatic islets
Drugbank entries Show/Hide entries for Anakinra